
How tech and collaboration are accelerating the development of T-cell engagers
Alistair Henry, Executive Vice President Chief Scientific Officer at UCB, explains that various factors that are helping drive the development of T-cell engagers (TCEs). Why is immunotherapy discovery constantly evolving? As scientists, we are trained to measure, analyse and interpret. We quantify binding affinities, map pathways, and build increasingly sophisticated models of disease. Read More














